ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 109,95
-1,07%
Dow Jones
42 579,08
0,00%
DAX
23 019,09
-1,83%
Brent Oil
70,315
1,41%
Bitcoin
88 860,41
-1,19%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Windtree Therapeutics Inc (WINT)

  7. Windtree Therapeutics Inc (WINT) Actualités

WINT

Windtree Therapeutics (WINT)

Windtree Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:WINT
DateHeureSourceTitreSymboleSociété
04/03/202514h00GlobeNewswire Inc.Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart FailureNASDAQ:WINTWindtree Therapeutics Inc
27/02/202514h00GlobeNewswire Inc.Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for IndiaNASDAQ:WINTWindtree Therapeutics Inc
18/02/202514h00GlobeNewswire Inc.Windtree Therapeutics, Inc. Announces Reverse Stock SplitNASDAQ:WINTWindtree Therapeutics Inc
12/02/202514h00GlobeNewswire Inc.Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics ConferenceNASDAQ:WINTWindtree Therapeutics Inc
03/02/202523h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
15/01/202514h00GlobeNewswire Inc.Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology PipelineNASDAQ:WINTWindtree Therapeutics Inc
13/01/202514h00GlobeNewswire Inc.Windtree Announces the Addition of Leanne Kelly to Its Board of DirectorsNASDAQ:WINTWindtree Therapeutics Inc
08/01/202522h25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:WINTWindtree Therapeutics Inc
08/01/202514h00GlobeNewswire Inc.Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology PipelineNASDAQ:WINTWindtree Therapeutics Inc
16/12/202414h00GlobeNewswire Inc.Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceNASDAQ:WINTWindtree Therapeutics Inc
09/12/202414h00GlobeNewswire Inc.Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaNASDAQ:WINTWindtree Therapeutics Inc
04/12/202414h00GlobeNewswire Inc.Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic TransactionNASDAQ:WINTWindtree Therapeutics Inc
27/11/202422h05GlobeNewswire Inc.Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
14/11/202414h53Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:WINTWindtree Therapeutics Inc
14/11/202414h00GlobeNewswire Inc.Windtree Announces Leadership Transition Plan With Industry VeteransNASDAQ:WINTWindtree Therapeutics Inc
04/11/202414h00GlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong KongNASDAQ:WINTWindtree Therapeutics Inc
30/10/202413h00GlobeNewswire Inc.Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3NASDAQ:WINTWindtree Therapeutics Inc
23/10/202414h00GlobeNewswire Inc.Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the WorldNASDAQ:WINTWindtree Therapeutics Inc
21/10/202414h00GlobeNewswire Inc.Windtree To Present at the ThinkEquity Conference on October 30thNASDAQ:WINTWindtree Therapeutics Inc
17/10/202414h15GlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for JapanNASDAQ:WINTWindtree Therapeutics Inc
09/10/202414h00GlobeNewswire Inc.Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial DesignNASDAQ:WINTWindtree Therapeutics Inc
09/10/202413h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WINTWindtree Therapeutics Inc
30/09/202414h15GlobeNewswire Inc.Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
26/09/202422h05GlobeNewswire Inc.Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ETNASDAQ:WINTWindtree Therapeutics Inc
25/09/202414h15GlobeNewswire Inc.Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
04/09/202414h00GlobeNewswire Inc.Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
04/09/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:WINTWindtree Therapeutics Inc
03/09/202415h10Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
03/09/202413h26Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:WINTWindtree Therapeutics Inc
23/08/202422h15Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:WINT

Dernières Valeurs Consultées

EU
RI
Pernod Ricard
COIN
ADAUSD
Cardano
EU
MC
Lvmh Moet Hennessy Louis...
EU
CAP
Capgemini
COIN
ETHUSD
Ethereum
EU
ACA
Credit Agricole
EU
DG
Vinci
COIN
BTCUSD
Bitcoin
NASDAQ
AAPL
Apple
EU
VIV
Vivendi
NYSE
KO
Coca Cola
NYSE
NKE
Nike
EU
PX1
CAC 40
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces